Program
ATM Inhibitor SYH2051
Also written as “SYH2051 tablets” and “SYH2051”.
Its studies are mostly in Breast Neoplasms · Head and Neck Neoplasms, led by CSPC Pharmaceutical Group.
Furthest: phase 2, since Jan 1, 20253 company-led studies, 3 open or runningNext primary completion: Jun 15, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 33 open or running | phase 2since Jan 1, 2025 | Aug 14, 2023 | Jun 15, 2027phase 2 · NCT06775236 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 14, 2023First study: phase 1 study in Head and Neck NeoplasmsFirst studyNCT06011291 · 73 planned · China
- Jan 1, 2025Phase 2 study in Breast NeoplasmsNCT06775236 · 410 planned
- Oct 27, 2026Phase 2 study in Advanced Solid TumorsNCT07911579 · 154 planned · China
Ahead
- Jun 15, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06775236
- Dec 30, 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07911579
TargetBeta
ATM →read by rule
“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, ”NCIt, by rule
Other programs on ATM
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911579Advanced Solid Tumors · China | 2 | Not yet recruiting | Dec 30, 2028 | 154 |
| NCT06775236Breast Neoplasms | 2 | Not yet recruiting | Jun 15, 2027 | 410 |
| NCT06011291Head and Neck Neoplasms · China | 1 | Recruiting | Dec 31, 2024 | 73 |
How it is read
Names in the registry
- “SYH2051 tablets”, 2 entries
- “SYH2051”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.